Literature DB >> 8096944

Ovarian stimulation and granulosa-cell tumour.

W Willemsen1, R Kruitwagen, B Bastiaans, T Hanselaar, R Rolland.   

Abstract

Ovarian stimulation in the treatment of infertility is far from physiological because patients and their ovaries are exposed to high concentrations of gonadotropins. Many studies have focused on the two most common side-effects of ovarian stimulation--ie, hyperstimulation and multiple pregnancy. We describe 12 patients in whom granulosa-cell tumour was discovered after ovarian stimulation treatment with clomiphene citrate and/or gonadotropins. Although we cannot prove a causal link between the tumour and the medication, investigations in animals have shown a relation between gonadotropin exposition and the development of granulosa-cell tumours. The possible relation of ovarian stimulation and granulosa-cell tumours in human beings has not been published before. We postulate three explanations for this finding; first, the granulosa-cell tumour is present in the ovary, waiting for a hormonal trigger; second, increased follicle stimulating hormone concentrations are oncogenic to granulosa cell; and third, the onset of the granulosa-cell tumour during ovarian stimulation is coincidental. We recommend that ovarian stimulation is done only if there is a valid indication after proper assessment of the ovaries, and that women who have had ovarian stimulation are followed for longer than at present.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096944     DOI: 10.1016/0140-6736(93)91071-s

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

1.  Luteinizing hormone induction of ovarian tumors: oligogenic differences between mouse strains dictates tumor disposition.

Authors:  R A Keri; K L Lozada; F W Abdul-Karim; J H Nadeau; J H Nilson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

Review 3.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Ovarian granulosa cell tumor presenting as Meigs' syndrome with elevated CA125.

Authors:  Kwon Choi; Hyun Jong Lee; Ji Cheul Pae; Suk Joong Oh; Seong Yong Lim; Eun Yoon Cho; Seung Sei Lee
Journal:  Korean J Intern Med       Date:  2005-03       Impact factor: 2.884

5.  Fertility drugs and the risk of breast and gynecologic cancers.

Authors:  Louise A Brinton; Vikrant V Sahasrabuddhe; Bert Scoccia
Journal:  Semin Reprod Med       Date:  2012-04-27       Impact factor: 1.303

6.  Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors.

Authors:  K A Risma; C M Clay; T M Nett; T Wagner; J Yun; J H Nilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Establishment and characterization of a human ovarian granulosa tumor cell line (HSOGT).

Authors:  Haruhiro Kondo; Kazushige Kiguchi; Asami Okamura; Yoshiaki Okuma; Tomohiro Iida; Yoichi Kobayashi; Masayuki Takagi; Bunpei Ishizuka; Isamu Ishiwata
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

Review 8.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2013-08-13

9.  Acute abdomen with hemoperitoneum in a postmenopausal woman.

Authors:  Tulon Borah; Ananya Das; Subrat Panda; Ahanthem Santa Singh
Journal:  J Midlife Health       Date:  2010-07

10.  Differential expression of GRK isoforms in nonmalignant and malignant human granulosa cells.

Authors:  Denise Walker King; Rosemary Steinmetz; Heather A Wagoner; Tamara S Hannon; Lin Yuan Chen; Erica A Eugster; Ora Hirsch Pescovitz
Journal:  Endocrine       Date:  2003-11       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.